Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound

Cancer Research

Volumn 70, Issue 18, 2010, Pages 7232-7241

  Peterson, Quinn P ^a   Hsu, Danny C ^b   Novotny, Chris J ^a   West, Diana C ^b   Kim, Dewey ^b   Schmit, Joanna M ^b   Dirikolu, Levent ^b   Hergenrother, Paul J ^a,b   Fan, Timothy M ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROCASPASE 3; S PAC 1; UNCLASSIFIED DRUG; (4-BENZYLPIPERAZIN-1-YL)ACETIC ACID (3-ALLYL-2-HYDROXYBENZYLIDENE)HYDRAZINE; CASPASE 3; HYDRAZONE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; DOG; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TUMOR REGRESSION; ANIMAL; C57BL MOUSE; DOG DISEASES; DRUG EFFECTS; ENZYMOLOGY; HELA CELL LINE; HUMAN; JURKAT CELL LINE; LYMPHOMA, B-CELL; METABOLISM; PATHOLOGY; TOXICITY; U937 CELL LINE; VETERINARY;

ANIMALS; APOPTOSIS; CASPASE 3; DOG DISEASES; DOGS; ENZYME ACTIVATION; HELA CELLS; HUMANS; HYDRAZONES; JURKAT CELLS; LYMPHOMA, B-CELL; MALE; MICE; MICE, INBRED C57BL; PIPERAZINES; U937 CELLS;

EID: 77956900533     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0766     Document Type: Article

References (36)

1. O'Donovan N, Crown J, Stunell H, et al. Caspase 3 in breast cancer. Clin Cancer Res 2003;9:738-42.
2. Roy S, Bayly CI, Gareau Y, et al. Maintenance of caspase-3 pro-enzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc Natl Acad Sci U S A 2001;98:6132-7.
3. Krepela E, Prochazka J, Liul X, Fiala P, Kinkor Z. Increased expression of Apaf-1 and procaspase-3 and the functionality of intrinsic apoptosis apparatus in non-small cell lung carcinoma. Biol Chem 2004;385:153-68.
4. Izban KF, Wrone-Smith T, Hsi ED, Schnitzer B, Quevedo ME, Alkan S. Characterization of the interleukin-1b-converting enzyme/Ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease. Am J Pathol 1999;154:1439-47.
5. Nakagawara A, Nakamura Y, Ikeda H, et al. High levels of expression and nuclear localization of interleukin-1 b converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res 1997;57:4578-84.
6. Fink D, Schlagbauer-Wadl H, Selzer E, et al. Elevated procaspase levels in human melanoma. Melanoma Res 2001;11:385-93.
7. Persad R, Liu C, Wu T-T, et al. Overexpression of caspase-3 in hepatocellular carcinomas. Mod Pathol 2004;17:861-7.
8. Putt KS, Chen GW, Pearson JM, et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2006;2:543-50.
9. Peterson QP, Goode DR,West DC, Ramsey KN, Lee J, Hergenrother PJ. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. J Mol Biol 2009;388:144-58.
10. Peterson QP, Hsu DC, Goode DR, Novotny CJ, Totten RK, Hergenrother PJ. Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of PAC-1, and its cellular co-localization with procaspase-3. J Med Chem 2009;52:5721-31.
11. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-56.
12. Peterson QP, Goode DR, West DC, Botham RC, Hergenrother PJ. Preparation of the caspase-3/7 substrate Ac-DEVD-pNA by solution-phase peptide synthesis. Nat Protoc 2010;5:294-302.
13. Huang S, Clark RJ, Zhu L. Highly sensitive fluorescent probes for zinc ion based on triazolyl-containing tetradentate coordination motifs. Org Lett 2007;9:4999-5002.
14. Brewster ME, Simpkins JW, Hora MS, Stern WC, Bodor N. The potential use of cyclodextrins in parenteral formulations. J Parenter Sci Technol 1989;43:231-40.
15. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001;74:983-6.
16. María-Isabel D, José-Miguel B-I, Carlos C, Juan N, Ana-Isabel M-M, Francisco-José M-G. Neural overexcitation and implication of NMDA and AMPA receptors in a mouse model of temporal lobe epilepsy implying zinc chelation. Epilepsia 2006;47:887-99.
17. Domínguez MI, Blasco-Ibez JM, Crespo C, Marqus-Mar AI, Martnez-Guijarro FJ. Zinc chelation during non-lesioning overexcitation results in neuronal death in the mouse hippocampus. Neuroscience 2003;116:791-806.
18. Clark DE. In silico prediction of blood-brain barrier permeation. Drug Discov Today 2003;8:927-33.
19. Lavoie N, Peralta MR III, Chiasson M, et al. Extracellular chelation of zinc does not affect hippocampal excitability and seizure-induced cell death in rats. J Physiol 2007;578:275-89.
20. Bose K, Pop C, Feeney B, Clark AC. An uncleavable procaspase-3 mutant has a lower catalytic efficiency but an active site similar to that of mature caspase-3. Biochemistry 2003;42:12298-310.
21. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112-6.
22. Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.
23. Franklin RB, Milon B, Feng P, Costello LC. Zinc and zinc transporters in normal prostate and the pathogenesis of prostate cancer. Front Biosci 2005;10:2230-9.
24. Aiuchi T, Mihara S, Nakaya M, Masuda Y, Nakajo S, Nakaya K. Zinc ions prevent processing of caspase-3 during apoptosis induced by geranylgeraniol in HL-60 cells. J Biochem (Tokyo) 1998;124:300-3.
25. Chai F, Truong-Tran AQ, Ho LH, Zalewski PD. Regulation of caspase activation and apoptosis by cellular zinc fluxes and zinc deprivation: a review. Immunol Cell Biol 1999;77:272-8.
26. Chimienti F, Seve M, Richard S, Mathieu J, Favier A. Role of cellular zinc in programmed cell death: temporal relationship between zinc depletion, activation of caspases, and cleavage of Sp family transcription factors. Biochem Pharmacol 2001;62:51-62.
27. Huesca M, Lock LS, Khine AA, et al. A novel small molecule with potent anticancer activity inhibits cell growth by modulating intracellular labile zinc homeostasis. Mol Cancer Ther 2009;8:2586-96.
28. Frederickson CJ, Koh J-Y, Bush AI. The neurobiology of zinc in health and disease. Nat Rev Neurosci 2005;6:449-62.
29. Karakas E, Simorowski N, Furukawa H. Structure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunit. EMBO J 2009;28:3910-20.
30. Adler M, Dinterman RE, Wannemacher RW. Protection by the heavy metal chelator N,N,N′,N′-tetrakis (2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B. Toxicon 1997;35:1089-100.
31. Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans - man and his best friend share more than companionship. Chromosome Res 2008;16:145-54.
32. Dorn CR, Taylor DO, Schneider R. The epidemiology of canine leukemia and lymphoma. Bibl Haematol 1970;36:403-15.
33. Kahl B. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma. Semin Hematol 2008;45:90-4.
34. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-9.
35. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120-4.
36. Rassnick KM, Mauldin GE, Al-Sarraf R, Mauldin GN, Moore AS, Mooney SC. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). J Vet Intern Med 2002;16:576-80.